# Microvast Holdings, Inc.: financial statements, quarterly

MVST · Nasdaq · CIK 1760689 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mvst.md) · [Financials](/companies/mvst/financials.md) · [Filings](/companies/mvst/filings.md) · [Insiders](/companies/mvst/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mvst/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [80.1](/filings/0001760689-25-000006.md) | [105 d](/filings/0001628280-26-018264.md) | [81.4](/filings/0001760689-25-000018.md) | [83.7](/filings/0001628280-25-039643.md) | [101](/filings/0001628280-25-051119.md) | [113 d](/filings/0001628280-26-018264.md) | [116](/filings/0001760689-25-000018.md) | [91.3](/filings/0001628280-25-039643.md) | [123](/filings/0001628280-25-051119.md) | [96.4 d](/filings/0001628280-26-018264.md) | [60.6](/filings/0001628280-26-033590.md) | [87.3](/filings/0001628280-26-055372.md) |
| Cost of revenue | $m | [62.2](/filings/0001760689-25-000006.md) | [81.6 d](/filings/0001760689-25-000010.md) | [64.1](/filings/0001760689-25-000018.md) | [56.5](/filings/0001628280-25-039643.md) | [67.8](/filings/0001628280-25-051119.md) | [71.9 d](/filings/0001760689-25-000010.md) | [73.5](/filings/0001628280-26-033590.md) | [59.6](/filings/0001628280-26-055372.md) | [76.9](/filings/0001628280-25-051119.md) | not reported | [41.5](/filings/0001628280-26-033590.md) | [61.5](/filings/0001628280-26-055372.md) |
| Gross profit | $m | [17.9](/filings/0001760689-25-000006.md) | [23.0 d](/filings/0001628280-26-018264.md) | [17.2](/filings/0001760689-25-000018.md) | [27.2](/filings/0001628280-25-039643.md) | [33.6](/filings/0001628280-25-051119.md) | [41.5 d](/filings/0001628280-26-018264.md) | [43.0](/filings/0001628280-26-033590.md) | [31.7](/filings/0001628280-26-055372.md) | [46.4](/filings/0001628280-25-051119.md) | [1.0 d](/filings/0001628280-26-018264.md) | [19.2](/filings/0001628280-26-033590.md) | [25.8](/filings/0001628280-26-055372.md) |
| Research and development | $m | [13.2](/filings/0001760689-25-000006.md) | [11.4 d](/filings/0001628280-26-018264.md) | [11.5](/filings/0001760689-25-000018.md) | [10.1](/filings/0001628280-25-039643.md) | [10.7](/filings/0001628280-25-051119.md) | [8.8 d](/filings/0001628280-26-018264.md) | [8.2](/filings/0001628280-26-033590.md) | [7.7](/filings/0001628280-26-055372.md) | [7.8](/filings/0001628280-25-051119.md) | [10.4 d](/filings/0001628280-26-018264.md) | [8.8](/filings/0001628280-26-033590.md) | [8.9](/filings/0001628280-26-055372.md) |
| Operating income | $m | [(26.3)](/filings/0001760689-25-000006.md) | [(22.2) d](/filings/0001628280-26-018264.md) | [(23.1)](/filings/0001760689-25-000018.md) | [(98.7)](/filings/0001628280-25-039643.md) | [7.2](/filings/0001628280-25-051119.md) | [(1.4) d](/filings/0001628280-26-018264.md) | [15.3](/filings/0001628280-26-033590.md) | [9.0](/filings/0001628280-26-055372.md) | [13.0](/filings/0001628280-25-051119.md) | [(41.2) d](/filings/0001628280-26-018264.md) | [(7.9)](/filings/0001628280-26-033590.md) | [(1.7)](/filings/0001628280-26-055372.md) |
| Interest expense | $m | [0.5](/filings/0001760689-23-000040.md) | [1.2 d](/filings/0001760689-24-000007.md) | [1.7](/filings/0001760689-24-000016.md) | [2.1](/filings/0001628280-25-039643.md) | [4.3](/filings/0001628280-25-051119.md) | [1.6 d](/filings/0001628280-26-018264.md) | [1.2](/filings/0001628280-26-033590.md) | [1.3](/filings/0001628280-26-055372.md) | [1.3](/filings/0001628280-25-051119.md) | [1.2 d](/filings/0001628280-26-018264.md) | [1.2](/filings/0001628280-26-033590.md) | [1.3](/filings/0001628280-26-055372.md) |
| Income tax | $m | [0.0](/filings/0001760689-25-000006.md) | [0.0 d](/filings/0001628280-26-018264.md) | [0.0](/filings/0001760689-25-000018.md) | [0.0](/filings/0001628280-25-039643.md) | [0.0](/filings/0001628280-25-051119.md) | [0.0 d](/filings/0001628280-26-018264.md) | [0.0](/filings/0001760689-25-000018.md) | [0.2](/filings/0001628280-26-055372.md) | [0.7](/filings/0001628280-25-051119.md) | [(6.3) d](/filings/0001628280-26-018264.md) | not reported | [0.0](/filings/0001628280-26-055372.md) |
| Net income | $m | [(26.1)](/filings/0001760689-25-000006.md) | [(24.5) d](/filings/0001628280-26-018264.md) | [(24.8)](/filings/0001760689-25-000018.md) | [(102)](/filings/0001628280-25-039643.md) | [13.2](/filings/0001628280-25-051119.md) | [(82.3) d](/filings/0001628280-26-018264.md) | [61.8](/filings/0001760689-25-000018.md) | [(106)](/filings/0001628280-26-055372.md) | [(1.5)](/filings/0001628280-25-051119.md) | [16.5 d](/filings/0001628280-26-018264.md) | [48.2](/filings/0001628280-26-033590.md) | [(12.0)](/filings/0001628280-26-055372.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001760689-25-000006.md) | not reported | [(0.08)](/filings/0001760689-25-000018.md) | [(0.32)](/filings/0001628280-25-039643.md) | [0.03](/filings/0001628280-25-051119.md) | not reported | [0.05](/filings/0001628280-26-033590.md) | [(0.33)](/filings/0001628280-26-055372.md) | [0.00](/filings/0001628280-25-051119.md) | not reported | [(0.04)](/filings/0001628280-26-033590.md) | [(0.03)](/filings/0001628280-26-055372.md) |
| Basic EPS | $ per share | [(0.08)](/filings/0001760689-25-000006.md) | not reported | [(0.08)](/filings/0001760689-25-000018.md) | [(0.32)](/filings/0001628280-25-039643.md) | [0.04](/filings/0001628280-25-051119.md) | not reported | [0.19](/filings/0001628280-26-033590.md) | [(0.33)](/filings/0001628280-26-055372.md) | [0.00](/filings/0001628280-25-051119.md) | not reported | [0.15](/filings/0001628280-26-033590.md) | [(0.03)](/filings/0001628280-26-055372.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [67.4](/filings/0001760689-25-000006.md) | [44.5](/filings/0001628280-26-018264.md) | [39.5](/filings/0001760689-25-000018.md) | [68.2](/filings/0001628280-25-039643.md) | [63.6](/filings/0001628280-25-051119.md) | [73.0](/filings/0001628280-26-018264.md) | [90.9](/filings/0001628280-26-033590.md) | [99.7](/filings/0001628280-26-055372.md) | [90.7](/filings/0001628280-25-051119.md) | [105](/filings/0001628280-26-055372.md) | [126](/filings/0001628280-26-033590.md) | [128](/filings/0001628280-26-055372.md) |
| Current assets | $m | [404](/filings/0001760689-23-000040.md) | [426](/filings/0001760689-25-000010.md) | [378](/filings/0001760689-24-000016.md) | [418](/filings/0001760689-25-000005.md) | [438](/filings/0001760689-25-000006.md) | [428](/filings/0001628280-26-018264.md) | [448](/filings/0001760689-25-000018.md) | [435](/filings/0001628280-25-039643.md) | [445](/filings/0001628280-25-051119.md) | [449](/filings/0001628280-26-055372.md) | [426](/filings/0001628280-26-033590.md) | [375](/filings/0001628280-26-055372.md) |
| Total assets | $m | [1,017](/filings/0001760689-23-000040.md) | [1,097](/filings/0001760689-25-000010.md) | [1,041](/filings/0001760689-24-000016.md) | [961](/filings/0001760689-25-000005.md) | [998](/filings/0001760689-25-000006.md) | [952](/filings/0001628280-26-018264.md) | [983](/filings/0001760689-25-000018.md) | [1,005](/filings/0001628280-25-039643.md) | [1,014](/filings/0001628280-25-051119.md) | [1,005](/filings/0001628280-26-055372.md) | [987](/filings/0001628280-26-033590.md) | [952](/filings/0001628280-26-055372.md) |
| Current liabilities | $m | [336](/filings/0001760689-23-000040.md) | [403](/filings/0001760689-25-000010.md) | [367](/filings/0001760689-24-000016.md) | [373](/filings/0001760689-25-000005.md) | [336](/filings/0001760689-25-000006.md) | [330](/filings/0001628280-26-018264.md) | [340](/filings/0001760689-25-000018.md) | [525](/filings/0001628280-25-039643.md) | [530](/filings/0001628280-25-051119.md) | [488](/filings/0001628280-26-055372.md) | [444](/filings/0001628280-26-033590.md) | [344](/filings/0001628280-26-055372.md) |
| Total liabilities | $m | [449](/filings/0001760689-23-000040.md) | [533](/filings/0001760689-25-000010.md) | [495](/filings/0001760689-24-000016.md) | [506](/filings/0001760689-25-000005.md) | [512](/filings/0001760689-25-000006.md) | [564](/filings/0001628280-26-018264.md) | [529](/filings/0001760689-25-000018.md) | [649](/filings/0001628280-25-039643.md) | [655](/filings/0001628280-25-051119.md) | [595](/filings/0001628280-26-055372.md) | [521](/filings/0001628280-26-033590.md) | [409](/filings/0001628280-26-055372.md) |
| Long-term debt | $m | [30.8](/filings/0001760689-23-000040.md) | [43.8](/filings/0001760689-25-000010.md) | [43.0](/filings/0001760689-24-000016.md) | [34.2](/filings/0001760689-25-000005.md) | [53.4](/filings/0001760689-25-000006.md) | [41.1](/filings/0001628280-26-018264.md) | [41.3](/filings/0001760689-25-000018.md) | [34.2](/filings/0001628280-25-039643.md) | [34.4](/filings/0001628280-25-051119.md) | [13.2](/filings/0001628280-26-018264.md) | not reported | not reported |
| Short-term borrowings | $m | [24.8](/filings/0001760689-23-000040.md) | [35.4](/filings/0001760689-25-000010.md) | [41.0](/filings/0001760689-24-000016.md) | [60.0](/filings/0001760689-25-000005.md) | [66.2](/filings/0001760689-25-000006.md) | [70.7](/filings/0001628280-26-018264.md) | [86.2](/filings/0001760689-25-000018.md) | [83.2](/filings/0001628280-25-039643.md) | [84.4](/filings/0001628280-25-051119.md) | [93.1](/filings/0001628280-26-018264.md) | [111](/filings/0001628280-26-033590.md) | [104](/filings/0001628280-26-055372.md) |
| Shareholders' equity | $m | [565](/filings/0001760689-23-000040.md) | [564](/filings/0001628280-26-018264.md) | [546](/filings/0001628280-25-039643.md) | [455](/filings/0001628280-25-051119.md) | [486](/filings/0001628280-25-051119.md) | [388](/filings/0001628280-26-055372.md) | [454](/filings/0001628280-26-055372.md) | [356](/filings/0001628280-26-055372.md) | [358](/filings/0001628280-25-051119.md) | [411](/filings/0001628280-26-055372.md) | [466](/filings/0001628280-26-055372.md) | [543](/filings/0001628280-26-055372.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(29.3)](/filings/0001760689-25-000006.md) | [(5.0) d](/filings/0001628280-26-018264.md) | [2.0](/filings/0001760689-25-000018.md) | [0.1 d](/filings/0001628280-25-039643.md) | [(5.4)](/filings/0001760689-25-000006.md) | [6.1 d](/filings/0001628280-26-018264.md) | [7.2](/filings/0001628280-26-033590.md) | [37.2 d](/filings/0001628280-26-055372.md) | [15.2 d](/filings/0001628280-25-051119.md) | [16.4 d](/filings/0001628280-26-018264.md) | [(22.8)](/filings/0001628280-26-033590.md) | [(10.5) d](/filings/0001628280-26-055372.md) |
| Capital expenditure | $m | [59.9 d](/filings/0001760689-25-000006.md) | [33.2 d](/filings/0001628280-26-018264.md) | [10.2](/filings/0001760689-25-000018.md) | [2.9 d](/filings/0001628280-25-039643.md) | [14.2 d](/filings/0001628280-25-051119.md) | [0.4 d](/filings/0001628280-26-018264.md) | [2.3](/filings/0001628280-26-033590.md) | [2.9 d](/filings/0001628280-26-055372.md) | [14.0 d](/filings/0001628280-25-051119.md) | [0.6 d](/filings/0001628280-26-018264.md) | [2.9](/filings/0001628280-26-033590.md) | [11.3 d](/filings/0001628280-26-055372.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [306](/filings/0001760689-23-000040.md) | [308](/filings/0001760689-24-000016.md) | [308](/filings/0001760689-25-000005.md) | [313](/filings/0001760689-25-000006.md) | [315](/filings/0001760689-25-000018.md) | [316](/filings/0001628280-25-039643.md) | [367](/filings/0001628280-25-051119.md) | [374](/filings/0001628280-26-033590.md) | [324](/filings/0001628280-26-055372.md) | [324](/filings/0001628280-25-051119.md) | [385](/filings/0001628280-26-033590.md) | [349](/filings/0001628280-26-055372.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 384,534,486 at 2026-08-03, from the cover of the [10-Q filed 2026-08-10](/filings/0001628280-26-055372.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.